CAS number：41575-94-4
molecular formula：C6H12N2O4Pt
molecular weight：371.25
EINECS number：255-446-0

English synonyms

PARAPLATIN;1,1-cyclobutanedicarboxylatediammineplatinum(ii);1-cyclobutanedicarboxylato(2-)-o,o’)-diammine((sp-4-2)-platinu;1-cyclobutanedicarboxylato)diammine-(cis-platinum(ii;DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II);CARBOPLATIN;CARBOPLATINUM;CIS-DIAMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM

Related categories

Antineoplastic drugs; other antineoplastic drugs; drugs; catalysis and inorganic chemistry; intermediates; platinum-containing catalysts; raw materials; general reagents; antineoplastic drugs and immunosuppressants; pharmaceutical raw materials; small molecule inhibitors; small molecule inhibitors , natural product; anti-tumor; platinum; broad-spectrum anti-tumor drug; reference substance-impurity reference substance; cell biology reagent; standard substance;
Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Antitumors for Research and Experimental Use;Biochemistry;Classes of Metal Compounds;Cyclobutanes & Cyclobutenes;Pt (Platinum) Compounds;Simple 4-Membered Ring Compounds;Transition Metal Compounds;Intermediates & Fine Chemicals ;anti-cancer;metal-ammine complexes;NEMAZINE;Anti cancer;Anti can;Inhibitors;API

Introduction

Carboplatin is the second-generation platinum antineoplastic drug. Its anticancer activity is similar to that of cisplatin, but nephrotoxicity, ototoxicity, neurotoxicity, especially gastrointestinal reactions, are significantly lower than cisplatin, and its antitumor spectrum is not as good as cisplatin. wide. Its mechanism of action is mainly to cause DNA inter-strand and intra-strand cross-linking, interfere with DNA molecules, and inhibit cellular DNA synthesis. It mainly acts on the N-7 and O-6 atoms of guanine in DNA to produce cytotoxicity. Because the cyclobutane ring in the carboplatin molecule is more stable as a ligand than the chloride ion group in cisplatin, it was initially thought that carboplatin may not have ototoxicity, nephrotoxicity, and neurotoxicity like cisplatin, but after systemic biological Medical evaluation and a large number of clinical trials have proved that although carboplatin's nephrotoxicity, bone marrow suppression, ototoxicity and neurotoxicity are not as serious as cisplatin, the damage to the body still cannot be ignored. There is cross-resistance between the anti-tumor effect of carboplatin and cisplatin in vivo, so tumor cells that are not sensitive to cisplatin are also resistant to carboplatin. Carboplatin not only inhibits tumor growth, but also has a certain radiosensitizing effect from studies on tumor strains in vitro and transplanted breast cancer mice.

White flocculent loose powder, sponge-like block, odorless. soluble in water. It is easy to decompose when exposed to light. Acute toxicity LD50 mice (mg/kg): 150 intraperitoneal injection, 140 intravenous injection. Acute toxicity LD50 rat (mg/kg): 85 intravenous injection.

●  The range of action of carboplatin is generally similar to that of cisplatin. The main advantage of this new analogue is its difference in toxicity. Carboplatin is currently used as a palliative treatment for recurrent ovarian cancer, including patients who have previously received cisplatin. Clinical studies have also pointed out that carboplatin can produce objective responses to head and neck tumors, small cell lung cancer, and seminoma of the testis.

●  At present, carboplatin is mainly used clinically for the treatment of small cell lung cancer, ovarian cancer, testicular cancer, germ cell tumor, thyroid cancer, nasopharyngeal cancer, and can also be used for cervical cancer, non-small cell lung cancer, esophageal cancer, seminoma, Malignant tumors such as bladder cancer, mesothelioma, pediatric brain tumors and other head and neck cancers. This product can be used in patients who cannot tolerate cisplatin due to renal impairment, intractable vomiting, hearing loss or neurotoxicity. It has no cross-resistance with other chemotherapeutics, and can be used alone or in combination with other chemotherapeutics, and can be combined with surgery and radiotherapy to improve the curative effect.

●  The second generation of platinum complex antineoplastic drugs. The anti-tumor spectrum and anti-tumor activity are similar to cisplatin, but the water solubility is better than cisplatin, and the toxicity to the kidney is also lower. It has a good curative effect on small cell lung cancer, ovarian cancer, head and neck squamous cell carcinoma, testicular tumor, malignant lymphoma, etc. It can also be used for cervical cancer, bladder cancer, etc.

●  The second-generation platinum-based anticancer drugs have basically the same functions and uses as cisplatin. It is more active than cisplatin on some tumors, and it is stronger than cisplatin as a radiosensitizer under hypoxic conditions. It is mainly used for ovarian cancer, testicular cancer, small cell lung cancer and head and neck cancer.

●  It is the second-generation platinum-based new anticancer drug. Its activity is comparable to that of cisplatin, and its biochemical properties and activity spectrum are also similar, but its toxicity and side effects are significantly lower than that of cisplatin.

●  Carboplatin is a platinum-based anticancer drug that damages DNA by forming intrastrand couplings to adjacent guanine residues. The anti-tumor effects of these drugs are achieved through loss of DNA mismatch repair (MMR vaccine) activity and induction of programmed cell death.

●  Potassium chloroplatinate reacts with N2H4, HCI, KI to obtain iodoplatinum (crude product), then reacts with DMF-EtOH to obtain cisiodoplatinum (excellent product), and then reacts with Ag2SO4 filtrate 1,1-cyclobutanedicarboxylate barium carboplatin (crude product) and then washed and dried to obtain carboplatin.

●  Potassium chloroplatinate reacts with hydrazine hydrochloride and potassium iodide to obtain cis-iodoplatinum, which can be purified by recrystallization from a mixture of dimethylformamide and ethanol. Add cis-iodoplatinum into water, slowly add silver sulfate, and react at 20-25°C for 2-3 hours. Filter out the insoluble matter, slowly add barium 1,1-cyclobutane dicarboxylate (obtained from the reaction of 1,1-cyclobutane dicarboxylic acid and barium hydroxide) into the filtrate, react at room temperature for 3-4 hours, and statically Set for more than 12h, filter, and evaporate the filtrate to dryness. The resulting solid was washed with water and 95% ethanol, respectively. Dry at about 60°C to obtain carboplatin. Yield 87.5%.

Team Presentation